ProCE Banner Activity

Renal Cell Carcinoma: Update on Clinical Data, Trials, and Guidance for Community Practice

Slideset Download
Download these expert-selected slides on treatments for early and later-stage renal cell carcinoma.

Released: October 21, 2022

Expiration: October 20, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Katy Beckermann, MD, PhD: consultant/advisor/speaker: Alpine Bioscience, Aravive, AstraZeneca, Aveo, BMS, Exelixis, Merck, Seagen, Sanofi. Research (paid to institution): Aravive, Arsenal, Pionyr

Naomi B. Haas, MD

Professor
Division of Hematology/Oncology
Director
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Naomi Haas, MD: consultant/advisor/speaker: Aveo, Eisai, Merck, Roche/Genentech.

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Eric Jonasch, MD: : Aravive, Aveo, Calithera, DAVA Oncology, Eisai, Exelixis, Genentech, Ipsen, Merck, NiKang, Novartis, Takeda; researcher: Arrowhead, Merck, NiKang.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS: consultant/advisor/speaker: Astellas, AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, EMD Serono, Exelixis, IMV, Infinity Pharma, Janssen, MEI, Merck, Natera, Pfizer, Regeneron, Seattle Genetics; researcher (paid to institution): Astellas, Bristol-Myers Squibb, Genentech, Merck.